Kyntra Bio
KYNB
110 hedge funds and large institutions have $59M invested in Kyntra Bio in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 44 reducing their positions, and 56 closing their positions.
2,991% more call options, than puts
Call options by funds: $1.73M | Put options by funds: $56K
0.35% less ownership
Funds ownership: 3.13% → 2.78% (-0.35%)
28% less funds holding
Funds holding: 152 → 110 (-42)
30% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 44
71% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 56
72% less capital invested
Capital invested by funds: $208M → $59M (-$149M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.55M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.54M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.45M |
| 4 |
Primecap Management
Pasadena,
California
|
+$1.65M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$9.06M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$6.8M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.2M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$2.65M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$1.96M |
KYNB Hedge Fund Activity: Q3 2023 in Review
110 of the 6,309 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q3 2023, worth a combined $59M — down 72% from $208M a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of KYNB and 16 opened new positions — a net loss of 40 holders — while 44 trimmed existing stakes and 31 added.
The largest buyer was Armistice Capital, adding an estimated $5.55M. The largest seller was Schroder Investment Management Group, exiting entirely with an estimated $9.06M sold.
- 110 institutional investors held Kyntra Bio (KYNB) as of Q3 2023, down from 152 in Q2 2023.
- Funds reported $59M of Kyntra Bio stock for Q3 2023, down 72% quarter-over-quarter.
- 16 funds opened new Kyntra Bio positions in Q3 2023 and 56 closed out, a net change of -40 holders.
- The largest Kyntra Bio buyer in Q3 2023 was Armistice Capital, an estimated $5.55M added.
- The largest Kyntra Bio seller in Q3 2023 was Schroder Investment Management Group, an estimated $9.06M sold.
Based on aggregated 13F filings for Q3 2023.